• Something wrong with this record ?

Functional characterization and immunogenicity of a novel vaccine candidate against tick-borne encephalitis virus based on Leishmania-derived virus-like particles

M. Zimna, G. Brzuska, J. Salát, P. Svoboda, K. Baranska, B. Szewczyk, D. Růžek, E. Krol

. 2023 ; 209 (-) : 105511. [pub] 20221227

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Tick-borne encephalitis virus (TBEV) is a major cause of neurological infections in many regions of central, eastern and northern Europe and northern Asia. In approximately 15% of cases, TBEV infections lead to the development of severe encephalitis or meningitis. The main route of TBEV transmission is tick bites; however, ingestion of dairy products from infected animals (goats, cattle and sheep) is also a frequent cause of the disease. Therefore, vaccination of livestock in virus endemic regions could also contribute to the decrease in TBEV infection among humans. Although few vaccines against TBEV based on inactivated viruses are available for humans, due to high costs, vaccination is not mandatory in most of the affected countries. Moreover, there is still no vaccine for veterinary use. Here, we present a characterization and immunogenicity study of a new potential TBEV vaccine based on virus-like particles (VLPs) produced in Leishmania tarentolae cells. VLPs, which mimic native viral particles but do not contain genetic material, show good immunogenic potential. For the first time, we showed that the protozoan L. tarentolae expression system can be successfully used for the production of TBEV virus-like particles with highly efficient production. We confirmed that TBEV recombinant structural proteins (prM/M and E) from VLPs are highly recognized by neutralizing antibodies in in vitro analyses. Therefore, VLPs in combination with AddaVax adjuvant were used in immunization studies in a mouse model. VLPs proved to be highly immunogenic and induced the production of high levels of neutralizing antibodies. In a challenge experiment, immunization with VLPs provided full protection from lethal TBE in mice. Thus, we suggest that Leishmania-derived VLPs may be a good candidate for a safe alternative human vaccine with high efficiency of production. Moreover, this potential vaccine candidate may constitute a low-cost candidate for veterinary use.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004719
003      
CZ-PrNML
005      
20230808104549.0
007      
ta
008      
230418s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.antiviral.2022.105511 $2 doi
035    __
$a (PubMed)36581050
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Zimna, Marta $u Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland. Electronic address: marta.zimna@phdstud.ug.edu.pl
245    10
$a Functional characterization and immunogenicity of a novel vaccine candidate against tick-borne encephalitis virus based on Leishmania-derived virus-like particles / $c M. Zimna, G. Brzuska, J. Salát, P. Svoboda, K. Baranska, B. Szewczyk, D. Růžek, E. Krol
520    9_
$a Tick-borne encephalitis virus (TBEV) is a major cause of neurological infections in many regions of central, eastern and northern Europe and northern Asia. In approximately 15% of cases, TBEV infections lead to the development of severe encephalitis or meningitis. The main route of TBEV transmission is tick bites; however, ingestion of dairy products from infected animals (goats, cattle and sheep) is also a frequent cause of the disease. Therefore, vaccination of livestock in virus endemic regions could also contribute to the decrease in TBEV infection among humans. Although few vaccines against TBEV based on inactivated viruses are available for humans, due to high costs, vaccination is not mandatory in most of the affected countries. Moreover, there is still no vaccine for veterinary use. Here, we present a characterization and immunogenicity study of a new potential TBEV vaccine based on virus-like particles (VLPs) produced in Leishmania tarentolae cells. VLPs, which mimic native viral particles but do not contain genetic material, show good immunogenic potential. For the first time, we showed that the protozoan L. tarentolae expression system can be successfully used for the production of TBEV virus-like particles with highly efficient production. We confirmed that TBEV recombinant structural proteins (prM/M and E) from VLPs are highly recognized by neutralizing antibodies in in vitro analyses. Therefore, VLPs in combination with AddaVax adjuvant were used in immunization studies in a mouse model. VLPs proved to be highly immunogenic and induced the production of high levels of neutralizing antibodies. In a challenge experiment, immunization with VLPs provided full protection from lethal TBE in mice. Thus, we suggest that Leishmania-derived VLPs may be a good candidate for a safe alternative human vaccine with high efficiency of production. Moreover, this potential vaccine candidate may constitute a low-cost candidate for veterinary use.
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a ovce $7 D012756
650    _2
$a skot $7 D002417
650    _2
$a protilátky virové $7 D000914
650    12
$a viry klíšťové encefalitidy $x genetika $7 D004669
650    12
$a virové vakcíny $7 D014765
650    12
$a Leishmania $7 D007891
650    12
$a klíšťová encefalitida $x prevence a kontrola $7 D004675
650    _2
$a neutralizující protilátky $7 D057134
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Brzuska, Gabriela $u Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland. Electronic address: gabriela.brzuska@phdstud.ug.edu.pl
700    1_
$a Salát, Jiří $u Laboratory of Emerging Viral Infections, Veterinary Research Institute, Hudcova 70, CZ, 62100, Brno, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ, 37005, Ceske Budejovice, Czech Republic. Electronic address: salat@vri.cz
700    1_
$a Svoboda, Pavel $u Laboratory of Emerging Viral Infections, Veterinary Research Institute, Hudcova 70, CZ, 62100, Brno, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ, 37005, Ceske Budejovice, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 735/5, CZ, 62500, Brno, Czech Republic; Faculty of Veterinary Medicine, University of Veterinary Sciences Brno, Palackeho Tr. 1946/1, 61242, Brno, Czech Republic. Electronic address: svoboda@vri.cz
700    1_
$a Baranska, Klaudia $u Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland. Electronic address: klaudia.baranska@phdstud.ug.edu.pl
700    1_
$a Szewczyk, Boguslaw $u Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland. Electronic address: boguslaw.szewczyk@biotech.ug.edu.pl
700    1_
$a Růžek, Daniel, $u Laboratory of Emerging Viral Infections, Veterinary Research Institute, Hudcova 70, CZ, 62100, Brno, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ, 37005, Ceske Budejovice, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 735/5, CZ, 62500, Brno, Czech Republic. Electronic address: ruzekd@paru.cas.cz $d 1981- $7 stk2008441707
700    1_
$a Krol, Ewelina $u Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland. Electronic address: ewelina.krol@biotech.ug.edu.pl
773    0_
$w MED00000480 $t Antiviral research $x 1872-9096 $g Roč. 209, č. - (2023), s. 105511
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36581050 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230808104546 $b ABA008
999    __
$a ok $b bmc $g 1925044 $s 1190928
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 209 $c - $d 105511 $e 20221227 $i 1872-9096 $m Antiviral research $n Antiviral Res $x MED00000480
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...